aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Recommendation of “Buy” by Brokerages

aTyr Pharma, Inc. (NASDAQ:ATYR) has been given a consensus recommendation of “Buy” by the seven brokerages that are covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $20.20.

A number of research firms have commented on ATYR. Wells Fargo & Company lifted their price objective on shares of aTyr Pharma from $17.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of aTyr Pharma in a research report on Wednesday, June 4th.

Institutional Investors Weigh In On aTyr Pharma

A number of institutional investors have recently modified their holdings of ATYR. Group One Trading LLC bought a new stake in shares of aTyr Pharma in the fourth quarter valued at about $26,000. Victory Capital Management Inc. bought a new stake in shares of aTyr Pharma in the fourth quarter valued at about $37,000. Y Intercept Hong Kong Ltd bought a new stake in shares of aTyr Pharma in the first quarter valued at about $38,000. Raymond James Financial Inc. bought a new stake in shares of aTyr Pharma in the fourth quarter valued at about $39,000. Finally, XTX Topco Ltd bought a new stake in shares of aTyr Pharma in the fourth quarter valued at about $40,000. Institutional investors own 61.72% of the company’s stock.

aTyr Pharma Trading Up 1.0%

ATYR stock opened at $5.22 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.79 and a quick ratio of 7.79. The company has a fifty day moving average price of $3.99 and a two-hundred day moving average price of $3.66. aTyr Pharma has a one year low of $1.46 and a one year high of $5.98. The stock has a market cap of $464.58 million, a price-to-earnings ratio of -6.44 and a beta of 0.88.

aTyr Pharma (NASDAQ:ATYR) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. Equities analysts anticipate that aTyr Pharma will post -0.91 EPS for the current year.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.